Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors.

ABSTRACT:

Background

Randomized trials have shown a survival benefit for fruquintinib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies, but real-world prognostic analyses have been seldom reported. We evaluated survival, safety outcomes, and predictive and prognostic factors in patients treated with fruquintinib in a real-life setting.

Methods

We conducted a multi-center study by collecting relevant data on patients with advanced colorectal cancer (CRC) who received fruquintinib, focusing on progression-free survival (PFS), overall survival (OS), and L3 skeletal muscle index (SMI), including safety follow-up.

Results

From January 2020 to January 2022, a total of 140 patients were selected and included in this study. The

SUBMITTER: Wang Y 

PROVIDER: S-EPMC11399836 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature